There’s a lot to be optimistic about in the Financial sector as 2 analysts just weighed in on BiomX (PHGE) and DraftKings (DKNG) with bullish sentiments.
BiomX (PHGE)
Chardan Capital analyst Keay Nakae reiterated a Buy rating on BiomX today and set a price target of $28.00. The company’s shares closed last Thursday at $5.96.
According to TipRanks.com, Nakae is a 4-star analyst with an average return of 7.0% and a 46.1% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Lineage Cell Therapeutics, and Emergent Biosolutions.
Currently, the analyst consensus on BiomX is a Moderate Buy with an average price target of $28.00.
See today’s analyst top recommended stocks >>
DraftKings (DKNG)
Rosenblatt Securities analyst Bernie McTernan maintained a Buy rating on DraftKings today and set a price target of $65.00. The company’s shares closed last Thursday at $41.25.
According to TipRanks.com, McTernan is a 4-star analyst with an average return of 20.6% and a 67.2% success rate. McTernan covers the Services sector, focusing on stocks such as Charter Communications, Penn National Gaming, and Peloton Interactive.
DraftKings has an analyst consensus of Moderate Buy, with a price target consensus of $58.06, a 41.8% upside from current levels. In a report issued on November 4, Credit Suisse also reiterated a Buy rating on the stock with a $76.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on DKNG:
